Bedrijfsoverzicht
Adial Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical entity dedicated to the research and development of therapeutic interventions designed for the treatment or prevention of addiction and associated disorders. The company operates within the Healthcare sector, specifically positioning itself in the Biotechnology industry, a field characterized by high capital expenditure and significant regulatory scrutiny regarding drug approval processes. According to the available data, the enterprise maintains a market capitalization of $2.24 million and employs a staff of five individuals. These financial figures indicate that Adial Pharmaceuticals is a micro-cap entity with a very small operational footprint, suggesting limited resources for large-scale commercialization efforts at this stage. The minimal revenue generation coupled with a low market cap reflects the typical profile of a company in early clinical development phases that has not yet achieved product commercialization or significant market penetration.
Financiële gezondheid
The company reports N/A for trailing twelve-month revenue and N/A for year-over-year revenue growth, while recording a net loss of $-7,977,171 and an EBITDA of $-7,798,897 over the trailing twelve months. The substantial gap between the reported N/A revenue and the significant negative net income highlights a cost structure heavily weighted toward research and development expenses rather than cost of goods sold, which is standard for pre-revenue biotechnology firms. The company generated a free cash flow of $-3,768,275, indicating a continuous burn rate that consumes liquid assets to fund ongoing clinical trials and operational overhead. Regarding profitability metrics, the gross margin stands at 0.0%, the operating margin is 0.0%, and the profit margin is 0.0%, a combination that signifies the company has not yet generated any positive gross revenue to cover direct costs or operating expenses. On the balance sheet, Adial Pharmaceuticals holds $5.88 million in cash and maintains zero debt, creating a scenario where total liabilities do not offset assets with leverage. The absence of debt results in a debt-to-equity ratio listed as N/A, suggesting a conservative capital structure that prioritizes solvency over leverage, although this conservatism is necessary given the negative earnings. Liquidity is supported by a current ratio of 4.42, which indicates that the company possesses 4.42 times the current assets necessary to cover its short-term obligations. Finally, the return on equity is recorded at -170.7% and the return on assets at -83.2%, metrics that reveal management is currently destroying shareholder value due to the lack of profitable operations and the high cost of equity capital required to sustain the venture.
Waarderingsbeoordeling
Valuation multiples for Adial Pharmaceuticals are distorted by its lack of earnings, as evidenced by a P/E ratio (TTM) of N/A and a forward P/E of -0.33. The negative forward P/E suggests that analysts or market models are projecting earnings before interest, taxes, depreciation, and amortization in the future, though the discrepancy between the N/A trailing P/E and the negative forward P/E implies significant uncertainty regarding the trajectory of future profitability. The price-to-book ratio is calculated at 0.33, indicating that the market values the company at roughly one-third of its book value, which typically reflects a market discount applied to speculative assets with no current cash flow generation. Alternative valuation metrics such as the price-to-sales ratio are listed as N/A due to the absence of sales data, while the EV/EBITDA stands at 0.47, a figure that is mathematically derived but offers limited traditional valuation context for a firm with negative earnings. In terms of price volatility, the stock has a 52-week high of $30.25 and a 52-week low of $1.54, meaning the current share price is trading significantly below the 52-week high and near the lower end of its historical trading range. The beta coefficient is 1.40, which indicates that the stock price is expected to be 40% more volatile than the broader market index, exposing investors to higher systematic risk.
Growth & Income
The company reports N/A for revenue growth and N/A for earnings growth, reflecting the fact that no meaningful historical sales data exists to establish a growth trajectory or compare earnings expansion against revenue. Consequently, it is not possible to determine if earnings are growing faster or slower than revenue because both metrics are currently non-existent, a common characteristic for clinical-stage biopharmaceutical companies prior to market launch. As a non-dividend payer, Adial Pharmaceuticals reports a dividend yield of N/A and a payout ratio of 0.0%, confirming that the company retains all available cash to fund its clinical development programs rather than distributing income to shareholders. This reinvestment strategy is standard for the industry, where capital is directed toward advancing the lead product, AD04, through Phase 3 clinical trials rather than providing income distributions. The overall growth and income profile is defined by a total absence of current financial returns, with the company relying entirely on existing cash reserves and potential future fundraising to sustain operations until product approval and commercialization occur.